Shots:
- The US FDA has approved IND application of IBI3032 to initiate P-I trial for cardiometabolic disorders
- The P-I trials will be initiated simultaneously in China & the US, with dosing in healthy & overweight or obese participants anticipated to start in H2’25
- IBI3032, an oral GLP-1 receptor agonist biased toward the cAMP pathway, showed 5–10x higher oral exposure at equivalent doses, with superior efficacy & favorable tolerability in GLP-1R KI DIO mice & obese monkey models
Ref: PRNewswire | Image: HUTCHMED| Press Release
Related News:- HUTCHMED and Innovent Biologics Report NMPA’s NDA Acceptance of Fruquintinib + Sintilimab for Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
